The presentations are routine scientific updates with no regulatory or financial catalysts. Monitor for future AXS-12 NDA filing timing and any solriamfetol label expansion updates as material next steps, but this filing provides no new trade-triggering information.
Price Chart
Executive Summary
Axsome Therapeutics presented new data on AXS-12 and solriamfetol at SLEEP 2026, including cognitive/functional outcomes from the Phase 3 ENCORE trial and post-hoc composite endpoint analyses. The presentations do not contain new regulatory milestones, financial results, or concrete catalysts—this is a routine scientific conference update without material new information for the stock.
Key Facts
- Presented Phase 3 ENCORE trial data for AXS-12 in narcolepsy with cataplexy at SLEEP 2026
- Presented post-hoc composite endpoint analysis of solriamfetol Phase 3 trials in narcolepsy and OSA
- Presented subgroup analysis from CRESCENDO survey on residual cataplexy symptom burden
- No new approvals, regulatory submissions, or financial guidance were announced
- Conference runs June 14-17, 2026 in Baltimore
Financial Impact
No financial figures disclosed; routine scientific conference presentations with no immediate revenue or cost impact
Risk Factors
- AXS-12 and solriamfetol pipeline progress remains subject to clinical and regulatory risks
- No new efficacy or safety signals that change the probability of approval
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3311661 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 11, 2026 7w ago | Institutional Cluster | $214.66 $211.12 | ▼ −1.65% | ▲ +0.25% | $176.95 (−17.57%) |
Aug 10, 2026 7w ago | 8-K | $220.89 $207.82 | ▼ −5.92% | ▼ −5.00% | $176.95 (−19.89%) |
Aug 10, 2026 7w ago | Press Release | $220.89 $207.82 | ▼ −5.92% | ▼ −5.00% | $176.95 (−19.89%) |
Jul 15, 2026 11w ago | Press Release | $237.53 $214.66 | ▼ −9.63% | ▼ −11.97% | $176.95 (−25.51%) |
Jul 9, 2026 12w ago | Court Ruling | $248.95 $210.13 | ▼ −15.59% | ▼ −17.84% | $176.95 (−28.92%) |
Jul 7, 2026 12w ago | Press Release | $249.76 $211.04 | ▼ −15.50% | ▼ −16.84% | $176.95 (−29.15%) |
Jul 1, 2026 13w ago | 144 | $244.31 $234.64 | ▼ −3.96% | ▼ −3.54% | $176.95 (−27.57%) |
Jun 15, 2026 15w ago | Press Release | $253.40 $228.28 | ▼ −9.91% | ▼ −9.16% | $176.95 (−30.17%) |
Jun 12, 2026 16w ago | Insider Cluster | $255.17 $233.80 | ▼ −8.37% | ▼ −10.15% | $176.95 (−30.66%) |
Jun 11, 2026 16w ago | 144 | $255.17 $233.80 | ▼ −8.37% | ▼ −10.15% | $176.95 (−30.66%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access